Company research
AbbVie Inc.
CIK 1551152Updated Sep 26, 2026
SecurityABBV · NYSE · equity
ABBV price & chart
Loading TradingView…
NYSE:ABBV on TradingView ↗About the company
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline - spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
In the news
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research ↗
AbbVie to Present at the Bank of America Securities Healthcare Conference ↗
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States News provided by AbbVie Jan 12, 2026, 06:00 ET Share this article Share to X Share this article Share to X Milestone marks progress against AbbVie's previously announced commitment ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
424B5 filing
Other Events
Items 8.01, 9.01
FWP filing
Show 5 more recent filings
424B5 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 133,960,000,000Source | 135,161,000,000Source | 134,711,000,000Source | 138,805,000,000Source |
| Property, Plant and Equipment, NetUSD | 5,628,000,000Source | 5,134,000,000Source | 4,989,000,000Source | 4,935,000,000Source |
| GoodwillUSD | 35,640,000,000Source | 34,956,000,000Source | 32,293,000,000Source | 32,156,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 52,641,000,000Source | 60,068,000,000Source | 55,610,000,000Source | 67,439,000,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,229,000,000Source | 5,524,000,000Source | 12,814,000,000Source | 9,201,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 12,589,000,000Source | 10,919,000,000Source | 11,155,000,000Source | 11,254,000,000Source |
| Inventory, NetUSD | 4,951,000,000Source | 4,181,000,000Source | 4,099,000,000Source | 3,579,000,000Source |
| Assets, CurrentUSD | 29,062,000,000Source | 25,582,000,000Source | 33,002,000,000Source | 28,463,000,000Source |
| Operating Lease, Right-of-Use AssetUSD | 737,000,000Source | 723,000,000Source | 744,000,000Source | 737,000,000Source |
| Other Assets, NoncurrentUSD | 10,721,000,000Source | 9,142,000,000Source | 8,513,000,000Source | 5,571,000,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | -15,493,000,000Source | -7,900,000,000Source | -1,000,000,000Source | 4,784,000,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,144,000,000Source | -1,925,000,000Source | -2,305,000,000Source | -2,199,000,000Source |
| Stockholders' Equity Attributable to ParentUSD | -3,270,000,000Source | 3,325,000,000Source | 10,360,000,000Source | 17,254,000,000Source |
| Additional Paid in Capital, Common StockUSD | 22,495,000,000Source | 21,333,000,000Source | 20,180,000,000Source | 19,245,000,000Source |
| Liabilities and EquityUSD | 133,960,000,000Source | 135,161,000,000Source | 134,711,000,000Source | 138,805,000,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 43,289,000,000Source | 38,749,000,000Source | 37,841,000,000Source | 29,538,000,000Source |
| Operating Lease, Liability, CurrentUSD | 194,000,000Source | 178,000,000Source | 166,000,000Source | 166,000,000Source |
| Accounts Payable, CurrentUSD | 3,592,000,000Source | 2,945,000,000Source | 3,688,000,000Source | 2,934,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 689,000,000Source | 697,000,000Source | 735,000,000Source | 754,000,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,389,000,000Source | 2,579,000,000Source | 1,952,000,000Source | 2,190,000,000Source |
| Other Liabilities, NoncurrentUSD | 32,569,000,000Source | 30,129,000,000Source | 32,327,000,000Source | 30,655,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 42,000,000Source | 39,000,000Source | 37,000,000Source | 33,000,000Source |
| Additional Financial Items | ||||
| Dividends Payable, CurrentUSD | 3,099,000,000Source | 2,936,000,000Source | 2,783,000,000Source | 2,680,000,000Source |
| Long-term DebtUSD | 64,503,000,000Source | 66,841,000,000Source | 59,245,000,000Source | 63,128,000,000Source |
| Short-term InvestmentsUSD | 28,000,000Source | 31,000,000Source | 2,000,000Source | 28,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 4,233,000,000Source | 4,286,000,000Source | 4,873,000,000Source | 11,845,000,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 955,000,000Source | 911,000,000Source | 747,000,000Source | 671,000,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,490,000,000Source | -207,000,000Source | -66,000,000Source | 1,455,000,000Source |
| Increase (Decrease) in InventoriesUSD | 234,000,000Source | 319,000,000Source | 417,000,000Source | 686,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | -492,000,000Source | -1,449,000,000Source | -2,889,000,000Source | -1,931,000,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 19,030,000,000Source | 18,806,000,000Source | 22,839,000,000Source | 24,943,000,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 204,000,000Source | 17,493,000,000Source | 0Source | 255,000,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,643,000,000Source | -20,820,000,000Source | -2,009,000,000Source | -623,000,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 29,000,000Source | -189,000,000Source | -13,000,000Source | -774,000,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,214,000,000Source | 974,000,000Source | 777,000,000Source | 695,000,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 980,000,000Source | 1,708,000,000Source | 1,972,000,000Source | 1,487,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -12,724,000,000Source | -5,211,000,000Source | -17,222,000,000Source | -24,803,000,000Source |
| Dividends paid | — | — | — | — |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | 68,000,000Source | 57,000,000Source | 48,000,000Source | 30,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -295,000,000Source | -7,290,000,000Source | 3,613,000,000Source | -545,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,229,000,000Source | 5,524,000,000Source | 12,814,000,000Source | 9,201,000,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,002,000,000Source | 2,811,000,000Source | 2,469,000,000Source | 2,546,000,000Source |
| Income Taxes Paid, NetUSD | 3,626,000,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 42,000,000Source | -65,000,000Source | 5,000,000Source | -62,000,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 955,000,000Source | 911,000,000Source | 747,000,000Source | 671,000,000Source |
| Amortization of Intangible AssetsUSD | 7,377,000,000Source | 7,622,000,000Source | 7,946,000,000Source | 7,689,000,000Source |
| DepreciationUSD | 762,000,000Source | 764,000,000Source | 752,000,000Source | 778,000,000Source |
| Dividends Payable, CurrentUSD | 3,099,000,000Source | 2,936,000,000Source | 2,783,000,000Source | 2,680,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -58,000,000Source | -21,000,000Source | -146,000,000Source | -148,000,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | 0Source | 0Source | 172,000,000Source |
| GoodwillUSD | 35,640,000,000Source | 34,956,000,000Source | 32,293,000,000Source | 32,156,000,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 847,000,000Source | 4,476,000,000Source | 4,229,000,000Source | 770,000,000Source |
| Income Tax Expense (Benefit)USD | 2,364,000,000Source | -570,000,000Source | 1,377,000,000Source | 1,632,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 4,226,000,000Source | 4,278,000,000Source | 4,863,000,000Source | 11,836,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 7,000,000Source | 8,000,000Source | 10,000,000Source | 9,000,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 4,186,000,000Source | 4,238,000,000Source | 4,820,000,000Source | 11,782,000,000Source |
| Other Nonoperating Income (Expense)USD | -5,793,000,000Source | -3,240,000,000Source | -4,677,000,000Source | -2,448,000,000Source |
| Other Operating Income (Expense), NetUSD | 241,000,000Source | 7,000,000Source | 179,000,000Source | -56,000,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 3,994,000,000Source | 16,963,000,000Source | — | 2,000,000,000Source |
| Proceeds from Stock Options ExercisedUSD | 172,000,000Source | 214,000,000Source | 180,000,000Source | 262,000,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 61,160,000,000Source | 56,334,000,000Source | 54,318,000,000Source | 58,054,000,000Source |
| Cost of RevenueUSD | 18,204,000,000Source | 16,904,000,000Source | 20,415,000,000Source | 17,414,000,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 14,010,000,000Source | 14,752,000,000Source | 12,872,000,000Source | 15,260,000,000Source |
| Operating Income (Loss)USD | 15,075,000,000Source | 9,137,000,000Source | 12,757,000,000Source | 18,117,000,000Source |
| Other Nonoperating Income (Expense)USD | -5,793,000,000Source | -3,240,000,000Source | -4,677,000,000Source | -2,448,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 6,597,000,000Source | 3,716,000,000Source | 6,250,000,000Source | 13,477,000,000Source |
| Income Tax Expense (Benefit)USD | 2,364,000,000Source | -570,000,000Source | 1,377,000,000Source | 1,632,000,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 7,000,000Source | 8,000,000Source | 10,000,000Source | 9,000,000Source |
| Net Income (Loss) Attributable to ParentUSD | 4,226,000,000Source | 4,278,000,000Source | 4,863,000,000Source | 11,836,000,000Source |
| Earnings Per Share, BasicUSD per share | 2.37Source | 2.4Source | 2.73Source | 6.65Source |
| Earnings Per Share, DilutedUSD per share | 2.36Source | 2.39Source | 2.72Source | 6.63Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,769,000,000Source | 1,769,000,000Source | 1,768,000,000Source | 1,771,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,773,000,000Source | 1,773,000,000Source | 1,773,000,000Source | 1,778,000,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 7,377,000,000Source | 7,622,000,000Source | 7,946,000,000Source | 7,689,000,000Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 6.65Source | 6.29Source | 5.99Source | 5.71Source |
| Costs and ExpensesUSD | 46,085,000,000Source | 47,197,000,000Source | 41,561,000,000Source | 39,937,000,000Source |
| Current Income Tax Expense (Benefit)USD | 2,856,000,000Source | 879,000,000Source | 4,266,000,000Source | 3,563,000,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -58,000,000Source | -21,000,000Source | -146,000,000Source | -148,000,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -3,540,000,000Source | -7,743,000,000Source | -3,475,000,000Source | -4,608,000,000Source |
| Interest ExpenseUSD | 2,893,000,000Source | 2,808,000,000Source | 2,224,000,000Source | 2,230,000,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -2,627,000,000Source | -2,160,000,000Source | -1,684,000,000Source | -2,044,000,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 4,186,000,000Source | 4,238,000,000Source | 4,820,000,000Source | 11,782,000,000Source |
| Other Operating Income (Expense), NetUSD | 241,000,000Source | 7,000,000Source | 179,000,000Source | -56,000,000Source |
Filing attachments
tm2624674d1_ex99-1.htm · 8-K · 2026-09-03
EX-99.1 2 tm2624674d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AbbVie Completes Acquisition of Apogee Therapeutics Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis Apogee's pipeline also includes APG273, a pote…
Read attachment ↗tm2623337d1_ex4-2.htm · 8-K · 2026-08-18
EX-4.2 2 tm2623337d1_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 Execution Version ABBVIE INC. SUPPLEMENTAL INDENTURE NO. 13 $500,000,000 Senior Floating Rate Notes due 2028 $1,000,000,000 4.500% Senior Notes due 2028 $1,250,000,000 4.650% Senior Notes due 2030 $1,500,000,000 4.875% Senior Notes due 2031 $1,250,000,000 5.050% Senior Notes due 2033 $1,500,000,000 5.300% Senior Notes due 2036 $1,000,000,000 5.450% Senior Notes due 2038 $1,500,000,000 6.000% Senior Notes due 2056 $500,000,000 6.…
Read attachment ↗abbv-20260630nonxgaapxex991.htm · 8-K · 2026-07-06
EX-99.1 2 abbv-20260630nonxgaapxex991.htm EX-99.1 Document AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended June 30, 2026 Full-Year Ended December 31, 2026 ────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗tm2618365d1_ex99-1.htm · 8-K · 2026-06-22
EX-99.1 2 tm2618365d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with a…
Read attachment ↗tm2618365d1_ex99-2.htm · 8-K · 2026-06-22
EX-99.2 3 tm2618365d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 1 Acquisition of Apogee Therapeutics June 22, 2026 ────────────────────────────────────── June 22, 2026 2 This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. All statements other than statements of h…
Read attachment ↗abbv-20260331nonxgaapxex991.htm · 8-K · 2026-04-03
EX-99.1 2 abbv-20260331nonxgaapxex991.htm EX-99.1 Document AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended March 31, 2026 Full-Year Ended December 31, 2026 ────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗